Clinical efficacy and data of tenofovir alafenamide fumarate tablets (Vemlidy) in the treatment of hepatitis B

Tenofovir alafenamide fumarate tablets (Vemlidy, trade name: Vemlidy) is a new type of nucleotide analogue, mainly used for antiviral treatment of patients with chronic hepatitis B (CHB). Its mechanism of action is by selectively inhibiting the activity of hepatitis B virus (HBV) DNA polymerase, blocking viral replication, thereby reducing serum HBV DNA levels. Compared with traditional tenofovir disoproxil disoproxil (TDF), tenofovir alafenamide fumarate has better renal and bone density safety with the same efficacy, so it is particularly suitable for patients with long-term medication or at risk of renal function.

Clinical studies have shown that Vemlidy has significant efficacy in inhibiting HBV replication. In a 48-week multi-center randomized controlled study, adult hepatitis B patients taking tenofovir alafenamide fumarate tablets had a significantly higher HBV DNA suppression rate than baseline, and most patients' serum HBV DNA levels dropped to undetectable levels. Compared with TDF, Vemlidy is equally effective in virological suppression, but shows advantages in improving renal function indicators and bone density, especially for patients requiring long-term antiviral treatment.

In clinical application, Vemlidy has shown good efficacy in both HBeAg positive and HBeAg negative patients. Research results show that HBeAgpositive patients can achieve HBeAgSeroconversion, that is, HBeAg changes from positive to negative, accompanied by a decrease in HBsAg levels, which provides an important indicator for improvement of liver function and long-term management of the disease. HBeAgnegative patients mainly through significant reductionHBV DNAlevels and improving liver function indicators (such asALT) to achieve clinical benefit.

Long-term follow-up data show that tenofovir alafenamide fumarate tablets have a lower incidence of drug resistance and are safer for patients to take. Common adverse reactions mainly include mild gastrointestinal discomfort, headache and fatigue, etc., and the incidence of serious adverse events is low. Overall, Vemlidy provides a safe and sustainable long-term treatment option for patients with chronic hepatitis B by effectively inhibiting HBV replication, improving liver function and protecting kidney and bone health. It is currently one of the important options for anti-HBV treatment.

Reference link:https://www.drugs.com